CytomX Therapeutics, Inc.
CTMX
$2.98
$0.041.36%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -177.57% | -240.44% | -348.06% | 97.64% | 70.58% |
| Total Depreciation and Amortization | -34.81% | 23.49% | -68.76% | -24.40% | -17.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.00% | 2.79% | 4.10% | 47.42% | 156.57% |
| Change in Net Operating Assets | 73.39% | 101.05% | 88.38% | -21.18% | -15.14% |
| Cash from Operations | -21.41% | -16.75% | 24.99% | 19.42% | 19.21% |
| Capital Expenditure | -- | -151.25% | 768.42% | 71.88% | -3.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -727.63% | -193.45% | -98.28% | -453.26% | -31.74% |
| Cash from Investing | -730.07% | -195.27% | -97.58% | -454.96% | -31.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 640.02% | -- | 1,734.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 640.02% | -- | 1,734.67% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 69.17% | -732.77% | -480.09% | -79.65% | -49.76% |